Mueller, M. C. and Gattermann, N. and Lahaye, T. and Deininger, M. W. N. and Berndt, A. and Fruehauf, S. and Neubauer, A. and Fischer, T. and Hossfeld, D. K. and Schneller, F. and Krause, S. W. and Nerl, C. and Sayer, H. G. and Ottmann, O. G. and Waller, C. and Aulitzky, W. and le Coutre, P. and Freund, M. and Merx, K. and Paschka, P. and Koenig, H. and Kreil, S. and Berger, U. and Gschaidmeier, H. and Hehlmann, R. and Hochhaus, A. (2003) Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. LEUKEMIA, 17 (12). pp. 2392-2400. ISSN 0887-6924
Full text not available from this repository.Abstract
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n = 69) or interferon (IFN)/Ara-C (n = 70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n = 803) and qualitative and quantitative RT-PCR from peripheral blood samples (n = 1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n = 48) vs 0.27% (IFN/Ara-C, n = 9, P = 0.025). BCR-ABL was undetectable in 25 cases by real-time PCR, but in only four patients by nested PCR. Median best response in patients with relapse after CCR was 0.24% (n = 3) as compared to 0.029% in patients with continuous remission (n = 52, P = 0.029). We conclude that (i) treatment with imatinib in newly diagnosed CML patients is associated with a rapid decrease of BCR-ABL transcript levels; (ii) nested PCR may reveal residual BCR-ABL transcripts in samples that are negative by real-time PCR; (iii) BCR-ABL transcript levels parallel cytogenetic response, and (iv) imatinib is superior to IFN/Ara-C in terms of the speed and degree of molecular responses, but residual disease is rarely eliminated.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHRONIC MYELOID-LEUKEMIA; POLYMERASE-CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; BONE-MARROW-TRANSPLANTATION; QUANTITATIVE RT-PCR; CHRONIC-PHASE; CYTOGENETIC RESPONSE; MOLECULAR RESPONSE; TRANSCRIPT LEVELS; FOLLOW-UP; quantitative PCR; BCR-ABL; chronic myelogenous leukemia; imatinib; interferon alpha |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Aug 2021 08:56 |
| Last Modified: | 25 Aug 2021 08:56 |
| URI: | https://pred.uni-regensburg.de/id/eprint/38369 |
Actions (login required)
 |
View Item |
